The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic. The vaccine — called Vaxzevria – was one of a number of shots released onto the market by pharmaceutical companies aimed at preventing people from catching COVID-19. The company said it would proceed to withdraw Vaxzevria's marketing authorizations within Europe. The vaccine was never approved in the U.S. by the FDA. POLAND ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by it ...

Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (NASDAQ:AZN) completed the additional equity investm ...

ToplineThe Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk’s diabetes drug Ozempic by making it harder to produce generic drugs.The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.NurPhoto via Getty Images Key FactsThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, Gl ...

A dad who suffered a brain injury just days after receiving a British-developed COVID vaccine has told Sky News he would never have had the jab if he had known of the risk of rare but serious side effects.Jamie Scott, who has two young boys and is now unable to work, is suing AstraZeneca for what he says is damage caused by the jab in April 2021. He alleges the pharmaceutical giant exaggerated the vaccine's effectiveness and downplayed its risks.AstraZeneca denies the claims made against them.In his first T ...

AstraZeneca’s (AZN) first-quarter 2024 core earnings of $1.03 per American depositary share (ADS) beat the Zacks Consensus Estimate of 95 cents. Core earnings of $2.06 per share rose 7% year over year on a reported basis and 13% at constant exchange rates (“CER”).Total revenues of $12.68 billion rose 17% on a reported basis and 19% at CER, driven by rising product sales and continued growth in Alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $11.92 billion.All g ...

Key TakeawaysAstraZeneca's sales of cancer drugs helped the pharmaceutical firm beat first-quarter estimates for earnings and revenue.Sales of oncology treatments rose 23%, and those for medicines made with partners jumped 59%.American depositary receipts (ADRs) of AstraZeneca traded near their all-time high on the news. American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter demand for its cancer drugs. Ast ...

AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Conference Call April 25, 2024 6:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and Chief Executive Officer Aradhana Sarin - Executive Director and Chief Financial Officer David Fredrickson - Executive Vice President of Oncology Susan Galbraith - Executive Vice President of Oncology R&D Ruud Dobber - Executive Vice President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice President of B ...

AstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales and continued growth in Alliance Revenue from partnered medicines. Core EPS increased 13% to $2.06. The increase in Core EPS was lower than total revenue growth mainly because of a $241m gain in the previous year’s ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant ...